Every 10-Q that Exicure, Inc. (XCUR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XCUR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XCUR filings page.
Exicure, Inc. reported no revenue for the three and six months ended June 30, 2026 and continues to focus on supporting GPCR Therapeutics USA’s clinical programs and exploring strategic alternatives. The company recorded a net loss of $1.1 million for the quarter and $2.9 million for the first half of 2026.
Cash and cash equivalents declined to $1.7 million, with total assets of $11.4 million and stockholders’ equity of $1.0 million. Management states there is substantial doubt about the ability to continue as a going concern without additional financing and is pursuing equity or debt funding and strategic transactions.
Operating expenses fell sharply year over year, with six‑month research and development expenses of $0.5 million and general and administrative expenses of $2.2 million, reflecting headcount reductions and cost controls. The company carries a Level 3 contingent consideration liability tied to milestones under its GPCR License and Collaboration Agreement and incurred fair value losses on this obligation. Exicure also discloses material weaknesses in internal control over financial reporting and ongoing Nasdaq listing compliance challenges due to low stockholders’ equity.
Exicure, Inc. reported a net loss of $1.8 million for the three months ended March 31, 2026, compared with net income of $3.0 million a year earlier. The swing was driven by the absence of a prior-year $6.0 million lease-termination gain and lower other income, partly offset by sharply reduced operating expenses.
The company generated no revenue, with research and development expense falling to $0.3 million and general and administrative expense to $1.3 million. Cash and cash equivalents were $2.6 million and stockholders’ equity $2.1 million as of March 31, 2026, while total liabilities reached $10.7 million, including $7.0 million of contingent consideration tied to the GPCR USA acquisition.
Management states there is substantial doubt about Exicure’s ability to continue as a going concern, citing ongoing losses, limited cash, and the need for additional financing to support operations and strategic alternatives. The company is exploring transactions around its GPCR USA oncology program, which completed a Phase 2 trial in January 2026, and expects to pay a $1.0 million milestone to GPCR in common stock.
Exicure discloses material weaknesses in internal control over financial reporting, multiple ongoing legal matters, and recent Nasdaq notices related to listing-rule compliance, including a deficiency triggered by the delayed filing of this report. Management indicates it is working to remediate controls and regain and maintain compliance, but acknowledges continued listing and financing uncertainties.
Exicure, Inc. reported Q3 2025 results marked by continued losses and tight liquidity. The company recorded no revenue and a net loss of $2.437 million for the quarter. Operating expenses were $2.391 million, led by $1.499 million in general and administrative costs and $0.888 million in research and development following the GPCR USA acquisition. Other items included a $155 thousand gain on settlement of payables and a $246 thousand increase in the fair value of contingent consideration.
Cash and cash equivalents were $4.438 million as of September 30, 2025, and management stated there is substantial doubt about the ability to continue as a going concern without additional financing. Year to date, results reflect a prior gain on early lease termination of $5.974 million and cash outflows from the acquisition of GPCR USA. The balance sheet includes intangible assets of $3.784 million and goodwill of $3.340 million from that deal, and a contingent consideration liability of $5.787 million tied to milestones, including $242 thousand classified as current. Common shares outstanding were 6,373,869 as of September 30, 2025.
Exicure, historically a nucleic-acid therapeutics company, completed the acquisition of GPCR USA and recorded identifiable intangible assets of $3.8M and $3.34M of goodwill. GPCR USA is running a Phase 2 trial of GPC-100 plus propranolol for stem cell mobilization and completed dosing of 20 patients, with results targeted for the fourth quarter of 2025. The acquisition included contingent consideration with a fair value of $5.541M tied to clinical and commercial milestones.
On the balance sheet, total assets were $18.738M with cash and cash equivalents of $7.858M (down from $12.508M). The company reported a quarterly net loss of $2.621M and an accumulated deficit of $198.875M, while six‑month net income of $0.389M reflected a $5.974M gain on early lease termination. Management discloses substantial doubt about the company’s ability to continue as a going concern and states additional financing is required.
Exicure, Inc. (Nasdaq: XCUR) filed its Form 10-Q for the quarter ended March 31, 2025. The filing confirms that the company remains a non-accelerated filer and smaller reporting company and is not a shell company. All required SEC reports and interactive data files have been submitted on time over the past 12 months. As of June 23 2025, the company had 6,317,793 common shares outstanding.
The document contains the standard sections—unaudited balance sheet, income statement, cash-flow statement, changes in stockholders’ equity, MD&A, risk factors and legal proceedings—yet the excerpt provided does not include actual financial figures or narrative discussion. Therefore, no assessment can be made regarding revenue, expenses, cash position, or profitability for the period.
Key structural disclosures gleaned from the excerpt:
- Headquarters: 400 Seaport Court, Suite 102, Redwood City, CA 94063; phone (847) 673-1700.
- Securities registered: Common Stock, $0.0001 par, trading symbol XCUR on Nasdaq.
- Table of contents shows Management’s Discussion begins on page 27 and Risk Factors on page 38, indicating extensive narrative sections.
- The cautionary note reiterates that forward-looking statements are subject to material risks, with reference to the detailed risk factors section.
Material information such as cash burn, R&D spend, and operating loss is not present in the excerpt. Investors will need to consult the full filing to evaluate liquidity runway, milestone obligations, and any updates on ongoing collaborations or litigation.